Biotin

January 5, 2018January 5, 2018

Top 10 Multiple Sclerosis Articles of 2017

News

Multiple Sclerosis News Today brought you daily coverage of important discoveries, treatment developments, clinical trials, and other events dealing with multiple sclerosis throughout 2017. We look ... Read more

January 3, 2018January 4, 2018

Turning Corners with MS: Ocrevus, Biotin, and 2018

Columns, MS in Motion - A Column by Mike Knight

Like a lot of people with MS, I took part in the “Great Ocrevus Rush of 2017,” with the fanfare surrounding the release of the first ... Read more

December 15, 2017December 14, 2017

Using Biotin? It Could Impact Your Lab Results

Columns, The MS Wire - A Column by Ed Tobias

Be careful if you’re using high-dose biotin (vitamin B7). The biotin in your blood could lead to some false readings when you have that blood tested. ... Read more

October 27, 2017October 30, 2017

#MSParis2017 – Potential Progressive MS Treatment on Move in US and Europe, MedDay CEO Says

News

This is a special edition of Multiple Sclerosis News Today’s daily Alexa Flash Briefing, covering the latest news from the 7th Joint ECTRIMS-ACTRIMS Meeting currently underway ... Read more

October 26, 2017October 26, 2017

#MSParis2017 – MedDay’s High-Dose Biotin, MD1003, Improves Disability in Progressive MS Patients

News

MD1003, a high-dose biotin developed by MedDay, slowed or prevented further disease progression among progressive multiple sclerosis (MS) patients in a Phase 3 clinical trial, researchers announced ... Read more

August 15, 2017August 16, 2017

An MS Study You Might Want to Join

Columns, The MS Wire - A Column by Ed Tobias

I was surprised to see that a study of a potential MS drug labeled MD1003 is still accepting participants. It’s a study that I’d love to ... Read more

July 25, 2017October 19, 2017

Could High-Dose Biotin Be Used as a Treatment for Multiple Sclerosis?

High-dose biotin, a B-complex vitamin, has been found to be an effective tool for slowing down multiple sclerosis (MS) in two clinical trials by MedDay Pharmaceuticals. According ... Read more

June 2, 2017June 2, 2017

#CMSC17 – Ocrevus, Progressive MS and Other Research Highlights: An Interview with CMSC’s Robert Lisak

News

The recent annual meeting of the Consortium of Multiple Sclerosis Centers (CMSC) brought researchers and healthcare professionals to New Orleans to discuss advances — and obstacles to advances ... Read more

May 22, 2017May 21, 2017

MS News that Caught My Eye: Risk Factors, Biotin and Symptoms, Pills, Shots or IVs, and More

Columns, The MS Wire - A Column by Ed Tobias

In case you missed them, here are some news stories that appeared in MS News Today that caught my eye over the past week. Ocrevus Market Entry ... Read more

May 9, 2017May 9, 2017

MedDay’s New Phase 3 Trial and Belief in Biotin’s Potential to Treat Progressive MS: An Interview with Dr. Frédéric Sedel

News

A global Phase 3 clinical trial assessing MD1003 — also known as high-dose biotin — for progressive multiple sclerosis (MS) might lead to the approval of one ... Read more

December 19, 2016January 2, 2017

High dose biotin protocol – my nine month update!

Columns, Faith of the Mustard Seed - a Column by Debi Wilson

Nine months ago I started the high dose biotin protocol. I did so in an effort to slow the progression of my primary progressive multiple sclerosis. ... Read more

November 3, 2016

Discussing Biotin as a Treatment for Multiple Sclerosis

In this video from MSWorldInc, Dr. Daniel Kantor speaks to Dr. Edward Fox, the Director of the MS Clinic of Central Texas about biotin and its ... Read more

August 29, 2016December 16, 2016

Riding the High-Dose Biotin Train for Progressive MS

Columns

I knew of no available treatment options for my Primary Progressive MS, so when I heard about the pure High Dose Biotin Protocol I jumped on ... Read more

May 13, 2016June 17, 2016

MedDay’s MD1003, a Biotin Shows ‘Remarkable’ Efficacy in Treating Inactive but Progressive MS in Clinical Trials  

The biotechnology company MedDay, recently disclosed full study results from the MS-SPI and MS-ON Phase 2b/3 trials of its drug product MD1003 in patients with multiple ... Read more

April 27, 2016May 25, 2016

MedDay’s MD1003, a Biotin, Shows ‘Remarkable’ Efficacy in Treating Inactive but Progressive MS in Clinical Trials

News

MedDay recently disclosed full study results from the MS-SPI and MS-ON Phase 2b/3 trials of its therapeutic candidate MD1003 in patients with multiple sclerosis (MS). Specifically, the trials ... Read more

October 13, 2015September 7, 2016

Insights into Promising MS Therapies at Late Breaking News Session, ECTRIMS 2015

News

A session titled “Late Breaking News” was featured at the 31st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), Oct. 7-10, ... Read more

April 23, 2015April 23, 2015

Phase III Study of Experimental MS Therapy Meets Primary Endpoint, Results to be Presented at ANN Meeting

Multiple Sclerosis News, News

MedDay, a French biotechnology company that studies treatments for nervous system disorders, including multiple sclerosis, announced that MD1003, a highly-concentrated biotin, is effective for treatment of progressive ... Read more

April 8, 2015June 11, 2015

MedDay Updates Status Of Pioneering Pivotal Phase III Study Design In Progressive Multiple Sclerosis

Multiple Sclerosis News, News

MedDay, a Paris, France based biotechnology company specializing in treatment of neurological disorders, has released more information regarding the design of its (MS-SPI) clinical trial that ... Read more